首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   48篇
  免费   2篇
基础医学   4篇
口腔科学   1篇
临床医学   8篇
内科学   1篇
特种医学   2篇
外科学   1篇
综合类   1篇
预防医学   23篇
药学   7篇
肿瘤学   2篇
  2023年   2篇
  2022年   3篇
  2021年   1篇
  2020年   5篇
  2019年   6篇
  2018年   3篇
  2017年   1篇
  2016年   2篇
  2015年   3篇
  2014年   5篇
  2013年   7篇
  2011年   1篇
  2010年   3篇
  2009年   4篇
  2008年   2篇
  2006年   1篇
  2003年   1篇
排序方式: 共有50条查询结果,搜索用时 15 毫秒
1.
医疗联合体是分级诊疗制度建立的重要部分,但在实践过程中医联体作用并未达到预期目标。本文通过查阅文献,采用行动者网络理论中的"转译"作为逻辑分析工具。通过"转译"分析区域医联体网络构建过程中遇到的障碍、参与者间的利益矛盾。研究认为,医联体涉及众多异质行动者,存在诸多矛盾和障碍,通过分析网络内各行动者的作用、利益和障碍,总结出政府的持续关注、上下级医院的协同合作以及充分利用网络技术是构建医联体并发挥作用的关键。本研究也会对政府在医联体中的正确定位,制定与优化相关医联体、分级诊疗机制和医保等政策具有参考价值。  相似文献   
2.
目的:为我国短缺药品监测预警体系更好的运行、实施提供参考。方法:基于利益相关者理论合理界定我国短缺药品监测预警过程中的利益相关者,分析各利益相关者在实现监测预警目标过程中拥有的"资源"及影响监测目标实现的"阻力"。结果:我国短缺药监测预警体系利益相关者主要包括政府部门、医疗机构、生产企业、流通企业、患者等,不同利益相关者之间有不同的"优势"与"劣势",在目标的达成过程中会遇到不同的"阻力"。结论:基于各利益相关者的利益诉求,妥善解决各利益相关者在实施过程中的困难,建立合理的利益平衡机制,才能带来理想的短缺药品监测预警实施效果。  相似文献   
3.
It was thought that several motivational theories might explain heroin use and account for the heterogeneity of personality traits found in the addict population. Greaves' existential theory and McClelland et al.'s conceptualization of the power motive were examined. These theories were operationalized and then compared with groups of addicts, alcoholics, and medical patients in a VA hospital. None of the hypotheses derived from the existential theory were supported. The power motivation theory gained considerable support in that addicts exhibited greater power concerns than the medical patients. It was found that addicts manifested an avoidance style of power concerns while the alcoholics showed more impulsive power strivings.  相似文献   
4.
PurposeThere is a critical need for genomic medicine research that reflects and benefits socioeconomically and ancestrally diverse populations. However, disparities in research populations persist, highlighting that traditional study designs and materials may be insufficient or inaccessible to all groups. New approaches can be gained through collaborations with patient/community stakeholders. Although some benefits of stakeholder engagement are recognized, routine incorporation into the design and implementation of genomics research has yet to be realized.MethodsThe National Institutes of Health–funded Clinical Sequencing Evidence-Generating Research (CSER) consortium required stakeholder engagement as a dedicated project component. Each CSER project planned and carried out stakeholder engagement activities with differing goals and expected outcomes. Examples were curated from each project to highlight engagement strategies and outcomes throughout the research lifecycle from development through dissemination.ResultsProjects tailored strategies to individual study needs, logistical constraints, and other challenges. Lessons learned include starting early with engagement efforts across project stakeholder groups and planned flexibility to enable adaptations throughout the project lifecycle.ConclusionEach CSER project used more than 1 approach to engage with relevant stakeholders, resulting in numerous adaptations and tremendous value added throughout the full research lifecycle. Incorporation of community stakeholder insight improves the outcomes and relevance of genomic medicine research.  相似文献   
5.
6.
参考国内外项目评价领域有关学者发表的文献,围绕利益相关者(Stakeholders)的核心概念,从项目评价目的中的功能和动机两个层面展开分析,对卫生项目评价的目的进行全面的阐述。  相似文献   
7.
8.
本文通过利益相关者理论分析,研究医患关系中的相关利益人,探求缓解医患关系的新路径,达到构建和谐医疗环境的目的。  相似文献   
9.
从利益相关者理论出发,对医师多点执业进行利弊分析,并提出完善相关法律法规、深化医药卫生体制改革、强化监督管理、更新医院管理模式、加强医德医风建设等建议,以期更好地推进医师多点执业在全国范围内的贯彻落实。  相似文献   
10.
This study explores the way the publication of a National White Book on health and safety risks that affect workers in jobs involving Nanotechnologies and Nanomaterials influenced the key Italian stakeholders attitude toward this issue and identifies the standpoints and priorities shared among researchers and stakeholders to develop a policy framework to address this issue.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号